Selective Therapeutic for C. diff Infection

Back to all technologies
Download as PDF
2018-RAMA-68247
Researchers at Purdue University have developed new drug candidates that promise to be effective in the treatment of Clostridium difficile Infection (CDI). This infection is the most common bacterial cause of antibiotic-associated diarrhea (AAD) with an estimated 500,000 cases annually resulting in approximately 29,000 deaths in the United States alone. Many patients treated with fidaxomicin, the only antibiotic approved for CDI in the past 40 years, experience a recurrence of CDI. The Purdue drug cures mice of CDI and prevents recurrence. The lead molecule is not toxic in mice or a human cell line. Further, this new therapeutic is selective for C. diff; it does not inhibit growth in representative species of normal gut microflora.

Advantages:

-New class of molecules against C. diff
-Does not inhibit growth of normal gut microflora
-Non-toxic in human cells and mice

Potential Applications:

-C. diff treatment
-Therapy for antibiotic-associated diarrhea and colitis
Feb 3, 2022
Provisional-Patent
United States
(None)
(None)

Aug 22, 2019
Provisional-Patent
United States
(None)
(None)

Aug 27, 2018
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org